As the CEO of Axsome Therapeutics, Herriot Tabuteau has been acutely aware of the fluctuations in his stock holdings. His most significant wealth was tied up in Axsome shares during key developmental phases of the company. Over the years, his...

As the CEO of Axsome Therapeutics, Herriot Tabuteau has been acutely aware of the fluctuations in his stock holdings. His most significant wealth was tied up in Axsome shares during key developmental phases of the company. Over the years, his compensation has seen considerable variation, with 2022 marking a peak with total earnings of over $1.3 million, which included a large bonus. In earlier years, he did not have vested stock compensation, focusing more on cash incentives instead. This strategy indicates a strategic choice to align with performance metrics rather than stock grants. It highlights a clear understanding of market dynamics and corporate growth, making him a significant figure in the biotech landscape.